AVEN, a cell death regulator, is an important signal inducer in acute leuke-mias. AVEN is a highly conserved peripheral membrane protein that protects the cell against the proteolytic activation of caspases as well as Apaf-1 mediated apoptosis by interfering with Apaf-1's ability to self-associate. Bcl-2 and Bad also interact with AVEN to prevent apoptosis. AVEN is highly expressed in ovary, heart, thymus, spleen, testis and colon, but can also be detected in other tissues. Erythropoietin and methylprednisolone may play important roles in the expression of AVEN in cardiac tissue, especially after a traumatic brain injury. In young patients suffering from acute lymphoblastic leukemia (ALL), AVEN expression may be a useful tool in prognosis prediction.
Aven Polyclonal Antibody detects endogenous levels of Aven protein.
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB: 1:500-1:2000, IHC-p: 1:100-1:300, IF: 1:200-1:1000, ELISA: 1:20000. Not yet tested in other applications.
Aven Polyclonal Antibody product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.
Find more details at http://www.abbkine.com/product/aven-polyclonal-antibody-abp50737.
bio-equip.cn
Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.